Updating results

1067 results

Sort: Relevance | Date

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults

Technology appraisal guidance Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults

Technology appraisal guidance Published August 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

HST10 Patisiran for treating hereditary transthyretin amyloidosis 1 Recommendations 1.1 Patisiran

Technology appraisal guidance

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published August 2019

Nusinersen for treating spinal muscular atrophy (TA588)

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Technology appraisal guidance Published July 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Technology appraisal guidance Published January 2019

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib

Technology appraisal guidance Published January 2019

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Technology appraisal guidance Published February 2019

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance Published February 2019

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published February 2019

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Technology appraisal guidance Published February 2019

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma

Technology appraisal guidance Published January 2019

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

Technology appraisal guidance Published January 2019

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years

Technology appraisal guidance Published December 2018

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Technology appraisal guidance Published January 2019

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

Technology appraisal guidance Published July 2019

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

Technology appraisal guidance Published October 2019

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published December 2015

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

Technology appraisal guidance Published July 2015

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Technology appraisal guidance Published December 2012 Last updated January 2015

Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for first-line treatment of multiple myeloma

Technology appraisal guidance Published July 2011

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer

Technology appraisal guidance Published March 2019

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...

Technology appraisal guidance Published June 2016

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Technology appraisal guidance Published February 2014

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer

Technology appraisal guidance Published August 2019

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

Proposed [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: TBC

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1584]

In development [GID-TA10533] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: 05 February 2020

Technology appraisal guidance In development